Thierry et al. (2014) found that ctDNA had a sensitivity of 92%, a specificity of 98%, and a net accuracy of 96% for KRAS mutations in mCRC patients. The prospective trial of Bachet et al. (2018) enrolled 425 mCRC patients to compare plasma with tissue RAS analysis, and results demonstrated 94.8% accuracy in 329 patients with detectable ctDNA. Some researchers believe that ctDNA represents the average tumor genome and may be a more accurate approach for mutation identification (Sartore-Bianchi et al., 2016a). This evidence concerns the gene KRAS and neoplasm.